Skip to main navigation Skip to search Skip to main content

Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

  • Kristian Steen Frederiksen*
  • , Mercè Boada
  • , Lutz Frölich
  • , Milica Kramberger
  • , Nikolaos Scarmeas
  • , Everard Vijverberg
  • , Pieter Jelle Visser
  • , Gunhild Waldemar
  • , Eric Westman
  • , Henrik Zetterberg
  • , Sebastiaan Engelborghs
  • , Frank Jessen
  • *Corresponding author for this work
Original languageEnglish
Article number100598
JournalJournal of Prevention of Alzheimer's Disease
Volume13
Issue number7
ISSN2274-5807
DOIs
Publication statusPublished - Aug 2026

Keywords

  • Alzheimer's disease
  • Anti-amyloid
  • Monocloncal antibodies

Cite this